Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2025-09-16 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于益丰大药房连锁股份有限公司向不特定对象发行可转换公司债券2025年第二次临时受托管理事务报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2025 Second Interim Trustee Management Affairs Report" related to a convertible bond issuance by Yifeng Pharmacy Chain Co., Ltd. It details the bond issuance, terms, adjustments to conversion price, dividend distributions affecting the bond, and trustee management activities. The document is a detailed report on the bond issuance and ongoing trustee management, including financial terms and bondholder rights, but it is not a full annual or interim financial report, nor an earnings release or audit report. It is a regulatory and trustee management report specific to the convertible bond issuance and its administration. This fits best under the category of Capital/Financing Update (CAP), as it concerns bond issuance and related financing activities and trustee management reports. The document length and detail confirm it is a substantive report, not just an announcement or certification, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2025-09-16 Chinese
益丰药房关于参加2025年湖南辖区上市公司投资者网上集体接待日暨半年度业绩说明会活动的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the company's participation in an investor online collective reception day and a half-year performance explanation meeting. It mentions the event date and topics to be discussed, including 2024 annual and 2025 half-year performance, governance, strategy, financing plans, and sustainability. The document does not contain actual financial statements or detailed financial data but rather informs about an upcoming event where such information will be discussed. The document length is short (663 characters) and serves as a notice or announcement rather than a report itself. Therefore, it fits best as an Investor Presentation (IP) announcement or related event notice. However, since it is announcing participation in a performance explanation meeting (which is typically an investor presentation), the most appropriate classification is Investor Presentation (IP).
2025-09-12 Chinese
益丰药房关于因权益分派调整可转债转股价格的公告
Capital/Financing Update Classification · 100% confidence The document is an official announcement from a company regarding the adjustment of the conversion price of its convertible bonds due to a dividend distribution. It details the adjustment formula, the dates of suspension and resumption of bond conversion, and references the bond issuance and related shareholder meetings. The document is short (2006 characters) and focuses on a specific capital/financing update related to convertible bonds and their conversion price adjustment. It is not a full financial report, earnings release, or regulatory certification. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-09-09 Chinese
益丰药房2025年半年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as a '2025 Half-Year Equity Distribution Implementation Announcement' from Yifeng Pharmacy Chain Co., Ltd. It details the dividend distribution plan for the 2025 half-year period, including dividend per share, relevant dates, tax treatment, and implementation methods. The document is an announcement of the dividend payment and related shareholder information, not a full financial report or earnings release. It does not contain comprehensive financial statements or management discussion but focuses on dividend distribution details. Therefore, it fits the category of 'Notice of Dividend Amount' (DIV). The document length is 2432 characters, which is consistent with an announcement rather than a full report.
2025-09-09 Chinese
益丰药房关于为控股子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Yifeng Pharmacy Chain Co., Ltd. regarding the progress of providing guarantees for its controlling subsidiary. It details the guarantee amount, the parties involved, internal decision procedures, financial data of the subsidiary, and the board's opinion on the guarantee. The document is an announcement about a financing-related guarantee activity rather than a financial report or audit. It does not contain financial statements or detailed financial performance data but focuses on the guarantee and related risk disclosures. The document length is 3129 characters, which is relatively short and typical for an announcement. Therefore, the document fits best under the category of Capital/Financing Update (CAP), which covers updates on company financing activities or capital structure changes such as guarantees provided for subsidiaries.
2025-09-03 Chinese
益丰药房关于实施2025年半年度权益分派时“益丰转债”停止转股的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (1303 characters) regarding the suspension of convertible bond conversion rights around the company's 2025 semi-annual dividend distribution. It details the dates of suspension and resumption of conversion rights, the dividend amount, and references prior board meeting resolutions and announcements. It does not contain financial statements or detailed financial data but rather informs about the operational details related to the dividend and bond conversion. This fits the category of a Capital/Financing Update (CAP) because it relates to convertible bond conversion suspension and dividend distribution arrangements, which are financing-related activities. The document is not a full financial report, earnings release, or regulatory filing of another type. Confidence is high due to clear content and context.
2025-09-03 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.